GS decreases Triglycerides

}

(BioMindmap Proof Quality is Acceptable.)

Gilbert's Syndrome decreases Triglycerides
(BioMindmap Proof Quality is Acceptable.)

2.5 ValidityScore

Valid or Invalid? Login to vote or flag.

Proofs

2018

Bilirubin acts as a multipotent guardian of cardiovascular integrity: more than just a radical idea.
Bulmer AC, et al.
«Bilirubin, a potentially toxic catabolite of heme and indicator of hepatobiliary insufficiency, exhibits potent cardiac and vascular protective properties. Individuals with Gilbert's syndrome (GS) may experience hyperbilirubinemia in response to stressors including reduced hepatic bilirubin excretion/increased red blood cell breakdown, with individuals usually informed by their clinician that their condition is of little consequence. However, GS appears to protect from all-cause mortality, with progressively elevated total bilirubin associated with protection from ischemic heart and chronic obstructive pulmonary disease. Bilirubin may protect against these diseases and associated mortality by reducing circulating cholesterol, oxidative lipid/protein modifications, and blood pressure. In addition, bilirubin inhibits platelet activation and protects the heart from ischemia-reperfusion injury. These effects attenuate multiple stages of the atherosclerotic process in addition to protecting the heart during resultant ischemic stress, likely underpinning the profound reduction in cardiovascular mortality in hyperbilirubinemic GS. This review outlines our current knowledge of and uses for bilirubin in clinical medicine and summarizes recent progress in revealing the physiological importance of this poorly understood molecule. We believe that this review will be of significant interest to clinicians, medical researchers, and individuals who have GS.»
Comments: Endothelial dysfunction contributes to the early stages of atherosclerosis, whereby 97 expression of adhesion molecules and oxidant generating NADPH oxidase (NOX) draws 98 leukocytes to sites of injury/lipid accumulation, propagating vascular injury and encouraging 99 vascular smooth muscle proliferation and neointima formation. Increased NOX driven 100 reactive oxygen species (ROS) production and intimal thickening contribute to hypertension 101 and impaired vasodilatation, involving sequestration of released nitric oxide. Based upon its 102 ROS neutralizing antioxidant properties, it is hypothesized that bilirubin has the potential to 103 reduce or prevent endothelial dysfunction.
#atherosclerosis, heart, heme oxygenase, hepatic, lipid
ncbi.nlm.nih.gov/pubmed/29600900
Read 10.1152/ajpheart.00417.2017

From this research we know that
2.5
Gilbert's Syndrome decreases Triglycerides
(BioMindmap Proof Quality is Acceptable.)
3.3
Gilbert's Syndrome may decrease Thrombosis
(BioMindmap Proof Quality is Acceptable.)
3.1
Gilbert's Syndrome may prevent Atherosclerosis
(BioMindmap Proof Quality is Acceptable.)
2.7
Gilbert's Syndrome inhibits Collagen
(BioMindmap Proof Quality is Acceptable.)
2.5
Gilbert's Syndrome decreases Cholesterol
(BioMindmap Proof Quality is Acceptable.)
7.0
Gilbert's Syndrome decreases LDL
+1
2.7
Atazanavir may worsen Gilbert's Syndrome
(BioMindmap Proof Quality is Acceptable.)
0.8
Gilbert's Syndrome may inhibit Atherosclerosis
(BioMindmap Proof Quality is Very Light.)
0.4
Gilbert's Syndrome may decrease Intima-media thickness
(BioMindmap Proof Quality is Very Light.)
0.8
Gilbert's Syndrome may cause Thrombocytopenia
(BioMindmap Proof Quality is Very Light.)
0.5
Bilirubin may cause Thrombocytopenia
(BioMindmap Proof Quality is Very Light.)
0.3
Bilirubin may cause Platelet apoptosis
(BioMindmap Proof Quality is Very Light.)
0.6
Gilbert's Syndrome may cause Platelet apoptosis
(BioMindmap Proof Quality is Very Light.)
0.5
Bilirubin may inhibit Thrombosis
(BioMindmap Proof Quality is Very Light.)
1.5
Bilirubin inhibits Collagen
(BioMindmap Proof Quality is Low.)
1.8
Bilirubin improves Atherosclerotic plaques
(BioMindmap Proof Quality is Low.)
1.6
Gilbert's Syndrome improves Atherosclerotic plaques
(BioMindmap Proof Quality is Low.)
1.8
Atazanavir increases Antioxidant capacity
(BioMindmap Proof Quality is Low.)
0.5
Atazanavir may decrease Blood pressure
(BioMindmap Proof Quality is Very Light.)
1.8
Atazanavir increases Bilirubin
(BioMindmap Proof Quality is Low.)
0.6
Exercise may worsen Gilbert's Syndrome
(BioMindmap Proof Quality is Very Light.)

2013

Protection from age-related increase in lipid biomarkers and inflammation contributes to cardiovascular protection in Gilbert's syndrome.
Wallner M, et al.
Pro-inflammatory markers
SAA is a pro-inflammatory adipokine in humans linked to
obesity and is a predictor of CVD [24,41]
Comments: Pro-inflammatory markers
SAA is a pro-inflammatory adipokine in humans linked to
obesity and is a predictor of CVD [24,41]
#Adult, Aging, Animal, Animals, Bilirubin, Biomarkers, Cardiovascular Diseases, Case-Control Studies, Disease Models, Female, Gilbert Disease, Gunn, Humans, Inflammation, Lipoproteins, Male, Middle Aged, Rats, Rats, Young Adult
ncbi.nlm.nih.gov/pubmed/23566065
Read 10.1042/CS20120661

From this research we know that
2.5
Gilbert's Syndrome decreases Triglycerides
(BioMindmap Proof Quality is Acceptable.)
4.1
Gilbert's Syndrome may decrease BMI
1.5
Gilbert's Syndrome may prevent CVD
(BioMindmap Proof Quality is Low.)
1.5
Gilbert's Syndrome may lower Serum Amyloid A
(BioMindmap Proof Quality is Low.)
1.8
Gilbert's Syndrome reduces Apolipoprotein B
(BioMindmap Proof Quality is Low.)
2.5
Gilbert's Syndrome decreases Cholesterol
(BioMindmap Proof Quality is Acceptable.)
5.1
Gilbert's Syndrome decreases IL-6
7.0
Gilbert's Syndrome decreases LDL
+1
1.5
Gilbert's Syndrome may increase Bilirubin
(BioMindmap Proof Quality is Low.)
1.4
Gilbert's Syndrome reduces Apo-A1
(BioMindmap Proof Quality is Low.)
1.8
Gilbert's Syndrome reduces SAA
(BioMindmap Proof Quality is Low.)
1.5
Serum Amyloid A is marker of CVD
(BioMindmap Proof Quality is Low.)
1.5
Apo-B/Apo-A1 ratio is marker of CVD
(BioMindmap Proof Quality is Low.)
0.6
Gilbert's Syndrome may reduce IDL-3
(BioMindmap Proof Quality is Very Light.)
-2.4
Perhaps, Gilbert's Syndrome may reduce LDL-1
(BioMindmap Proof Quality is Negative.) (BioMindmap had flagged this statement.)
1.8
IL-6 induces CRP
(BioMindmap Proof Quality is Low.)
0.8
CRP may increase CVD
(BioMindmap Proof Quality is Very Light.)
0.6
CRP may increase Diabetes Type 2
(BioMindmap Proof Quality is Very Light.)
0.6
Gilbert's Syndrome may decrease IDL
(BioMindmap Proof Quality is Very Light.)
0.8
Gilbert's Syndrome may decrease VLDL
(BioMindmap Proof Quality is Very Light.)
0.6
Gilbert's Syndrome may decrease Apo-B/Apo-A1 ratio
(BioMindmap Proof Quality is Very Light.)

Add Biolink with same Proofs

Add extra Proof

ranked

Gilbert's Syndrome decreases Triglycerides (BioMindmap Proof Quality is Acceptable.)

Proofs

Gilbert's Syndrome decreases Triglycerides
(BioMindmap Proof Quality is Acceptable.)